Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) (NCT05587712)
A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children From 1 to Less Than 18 Years of Age With PAH on Standard of Care
🩺 Plain-English Summary (8th-Grade Level)
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Who can join: Review the eligibility criteria below.
Location: The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606) — Los Angeles, California
Age range: 1 Year to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (35 Sites)
Showing the first 25 of 35 sites.
- The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606) — Los Angeles, California
- Stanford University School of Medicine ( Site 1603) — Palo Alto, California
- UCSF Benioff Children's Hospital San Francisco ( Site 1611) — San Francisco, California
- Children's Hospital Colorado ( Site 1609) — Aurora, Colorado
- Children's National Medical Center ( Site 1600) — Washington D.C., District of Columbia
- Cincinnati Children's Hospital Medical Center ( Site 1602) — Cincinnati, Ohio
- Children's Hospital of Philadelphia (CHOP) ( Site 1608) — Philadelphia, Pennsylvania
- Monroe Carell Jr. Children's Hospital ( Site 1601) — Nashville, Tennessee
- Seattle Children's Hospital ( Site 1605) — Seattle, Washington
- Children's Wisconsin ( Site 1610) — Milwaukee, Wisconsin
- The Children's Hospital at Westmead ( Site 0001) — Westmead, New South Wales
- Clinica Somer-Unidad de Investigacion y Docencia ( Site 0205) — Rionegro, Antioquia
- Fundación Valle del Lili ( Site 0200) — Cali, Valle del Cauca Department
- Clínica Imbanaco S.A.S ( Site 0203) — Cali, Valle del Cauca Department
- CHU de Toulouse - Hôpital des Enfants ( Site 0302) — Toulouse, Haute-Garonne
- Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 0303) — Marseille, Provence-Alpes-Côte d'Azur Region
- Hôpital Universitaire Necker Enfants Malades ( Site 0300) — Paris,
- Universitaetsklinikum Heidelberg ( Site 0401) — Heidelberg, Baden-Wurttemberg
- Klinikum der Universität München Großhadern ( Site 0404) — München, Bavaria
- Medizinische Hochschule Hannover ( Site 0405) — Hanover, Lower Saxony
- Schneider Children's Medical Center ( Site 0603) — Petah Tikva,
- Sheba Medical Center ( Site 0601) — Ramat Gan,
- University Medical Center Groningen ( Site 0900) — Groningen,
- Centrum Zdrowia Dziecka w Warszawie-Klinika Kardiologii ( Site 1103) — Warsaw, Masovian Voivodeship
- Uniwersyteckie Centrum Kliniczne-Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca ( Site 1102) — Gdansk, Pomeranian Voivodeship
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) — Aurora, Colorado
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension — Phoenix, Arizona
- Pulmonary Vascular Disease Phenomics Program PVDOMICS — Tucson, Arizona
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) — Jacksonville, Florida
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Aurora, Colorado
- ADAPT - A Patient Registry of the Real-world Use of Orenitram® — Fresno, California
Explore by condition: All Pulmonary Arterial Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.